Summary

Heart disease is one of the leading causes of death in China, and it is becoming increasingly common. As a result, the demand for ECG technology to identify and track cardiac disease is increasing. China's increasing middle class and greater income levels are driving up healthcare spending. This broadens the pool of prospective customers for companies that manufacture ECG products. Investments in healthcare technology and infrastructure are just two of the measures put in place by the Chinese government to improve the quality of healthcare in the country. The National Medical Goods Administration (NMPA) is the primary regulatory organisation in China for ECG goods. The NMPA regulates the safety, effectiveness, and quality of ECG equipment. ECG equipment must be registered with the NMPA before it can be distributed in China. Testing and assessment are part of the registration process to ensure that the equipment meets regulatory criteria. Chinese Good Manufacturing Practice (GMP) laws compel ECG manufacturers to adhere to quality control requirements. These laws are intended to ensure the uniform and secure manufacture of medical equipment. In China, the National Healthcare Security Administration (NHSA) oversees ECG equipment reimbursement criteria. The decision on whether ECG equipment is eligible for reimbursement and how much reimbursement will be paid is determined by the NHSA. China is a hub of medical technology innovation, particularly ECG equipment. ECG technology is constantly evolving in the market, with businesses offering portable, wireless, and AI-integrated ECG solutions. China's ongoing healthcare reforms and growing urbanisation have boosted healthcare knowledge and accessibility, resulting in increased demand for medical devices such as ECG machines, particularly in metropolitan areas. With an ageing population, there is a growing demand for cardiac care. This demographic trend contributes to an increase in the demand for ECG devices used to diagnose and monitor numerous heart diseases common in the elderly.

According to the research report "China Electrocardiograph (ECG) Market Overview, 2028," published by Bonafide Research, the China Electrocardiograph (ECG) market was valued more than USD 500 Million in 2022. In China, ECG equipment is progressively incorporating AI algorithms and utilising big data analytics for better diagnosis and prediction analysis. These innovations improve ECG machine diagnostic capabilities, assisting healthcare professionals in decision-making. Significant expenditures are being made in clinical research and development in China's ECG market. Companies and organisations work together on cutting-edge projects to increase the accuracy, efficiency, and accessibility of ECG technology. The Chinese government's interest in digital health and smart healthcare solutions extends to ECG gadgets. Integrating with digital health platforms and electronic health records (EHRs) improves data accessibility, allowing for more efficient patient management and healthcare coordination. Consumers growing health consciousness has resulted in the popularity of wearable ECG devices for personal health monitoring. This growth is consistent with China's growing emphasis on preventative healthcare, which is driving up sales of consumer-oriented ECG equipment. The vast scale of China's ECG market is due to its massive population. Because of the high demand for ECG equipment, the scale poses both a difficulty and an opportunity for manufacturers. China's demographic concerns, particularly a rapidly ageing population, necessitate special healthcare needs. The market's path is being shaped by an increasing need for cardiac care and diagnostic tools to manage age-related cardiovascular diseases. China has a robust ecosystem of local manufacturers producing ECG devices. This intense competition, both domestically and with international players, drives innovation and product diversification.

Based on product market is segmented into resting electrocardiograph (ECG), stress electrocardiograph (ECG), holter monitors, event recorders and others. Among them resting electrocardiograph (ECG) product is widely preferred ECG device in China and is anticipated to dominate the China Electrocardiograph (ECG) market. Resting ECG devices are useful and important for cardiac diagnosis. They provide a comprehensive analysis of the electrical activity of the heart at rest, which aids in the detection of various cardiac conditions. This adaptability meets a wide range of diagnostic requirements in a variety of healthcare settings. In general care and routine screenings, resting ECGs are routinely employed. Resting ECGs are a recommended initial diagnostic technique for identifying probable cardiac problems in China's healthcare system, which emphasises early identification and preventive intervention. The enormous population of China necessitates effective and scalable diagnostic solutions. Resting ECGs allow for rapid assessments and screenings, making them ideal for dealing with the high patient volume encountered in many healthcare facilities around the country. Based on end user segment market includes hospitals & clinics, home settings & ambulatory surgical centers (ASCs) and others. Home settings & ambulatory surgical centers (ASCs) is one of key end user of electrocardiograph (ECG) product in China. The developing healthcare models in China place an emphasis on patient empowerment and proactive health management. ECG devices in the home allow people with cardiac diseases to regularly check their heart health, allowing for early diagnosis of anomalies or changes and promoting self-care. In China, telemedicine projects emphasise remote consultations and monitoring. ECG equipment designed for home usage communicates with telemedicine systems, allowing healthcare experts to examine and manage patient’s cardiac health remotely, improving accessibility and convenience. In-home and ASC ECG equipment provide cost-effective and efficient diagnostic solutions. Continuous monitoring in the home and prompt assessment in ASCs help to ensure early interventions and efficient patient treatment.

Considered in this report:
• Geography: China
• Historic year: 2017
• Base year: 2022
• Estimated year: 2023
• Forecast year: 2028

Aspects covered in this report:
• China Electrocardiograph (ECG) market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Product:
• Resting Electrocardiograph (ECG)
• Stress Electrocardiograph (ECG)
• Holter Monitors
• Event Recorders
• Others

By End User:
• Hospitals & Clinics
• Home Settings & Ambulatory Surgical Centers (ASCs)
• Others

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, and annual reports of companies, analyzing the government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers into regional aspects, tier aspects, age groups, and gender. Once we have primary data with us we started verifying the details obtained from secondary sources.

Intended audience:
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the Electrocardiograph (ECG) industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

ページTOPに戻る

Table of Contents